US Food and Drug Administration advisory panels should continue to require a vote on the benefit/risk profile of new devices up for panel review but might not need voting consumer and patient representatives.
Those were some of the conclusions from a recent survey conducted by DC-based consultancy 3D, which was released on 13 August. The 414 respondents included 77 individuals who had...